Bio-Ridge NMN 23000+ Tablets

Australia - English - Department of Health (Therapeutic Goods Administration)

Buy It Now

Active ingredient:
Biotin,chromium picolinate,cyanocobalamin,Centipeda cunninghamii,Curcuma longa,folic acid,heavy magnesium oxide,leucine,nicotinamide,nicotinic acid,pyridoxine hydrochloride,Piper nigrum,quercetin,riboflavin,Reynoutria japonica,Terminalia ferdinandiana,ubidecarenone
Available from:
Australia Biotechnology Group Pty Ltd
Authorization status:
Authorization number:

Public Summary

Summary for ARTG Entry:


Bio-Ridge NMN 23000+ Tablets

ARTG entry for

Medicine Listed


Australia Biotechnology Group Pty Ltd

Postal Address

Factory 1/272-282 Frankston-Dandenong Road,Dandenong South, VIC, 3175


ARTG Start Date


Product category




Approval area

Listed Medicines


Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in

the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine,

(b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is

sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be


The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records

to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted

in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office

of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors

of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified

of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine

outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National

Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.


1. Bio-Ridge NMN 23000+ Tablets

Product Type

Single Medicine Product

Effective date


Permitted Indications

Antioxidant/Reduce free radicals formed in the body

Helps reduce/decrease free radical damage to body cells

Maintain/support energy levels

Maintain/support general health and wellbeing

Anti-inflammatory/relieve inflammation in healthy individuals

Maintain/support healthy blood circulation in healthy individuals

Helps maintain/support healthy blood sugar/glucose in healthy individuals

Maintain/support cardiovascular system health

Maintain/support healthy cardiovascular system function

Maintain/support blood vessel health in healthy individuals

Aid/assist/helps glucose/sugar/carbohydrate metabolism in healthy individuals

Helps prevent dietary (state vitamin/mineral/nutrient) deficiency

Helps enhance/promote skin health

Maintain/support skin health

Indication Requirements

Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.

Product presentation must not imply or refer to serious cardiovascular conditions.

Product presentation must not imply or refer to circulatory disorders/diseases/conditions e.g. thrombosis.

Label statement: If symptoms persist, talk to your health professional.

Public Summary

Page 1 of

Produced at 29.08.2019 at 04:37:22 AEST

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit for contact information

Label statement: Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not

replace a balanced diet.

Product presentation must not imply or refer to imply chronic fatigue syndrome.

Standard Indications

No Standard Indications included on Record

Specific Indications


If symptoms persist consult your healthcare practitioner (or words to that effect).

Do not take while on warfarin therapy without medical advice.

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule


1. Formulation 1

Dosage Form

Tablet, film coated

Route of Administration


Visual Identification

Active Ingredients


1 mg

Centipeda cunninghamii

25 mg

Equivalent: Centipeda cunninghamii (Dry)

250 mg

chromium picolinate

65 microgram

Curcuma longa

19.87 mg


200 microgram

folic acid

50 microgram

heavy magnesium oxide

25 mg


25 mg


50 mg

nicotinic acid

100 mg

Piper nigrum

5 mg

Equivalent: Piper nigrum (Dry)

250 mg

pyridoxine hydrochloride

1 mg


200 mg

Reynoutria japonica

60 mg

Equivalent: Reynoutria japonica (Dry)


1 mg

Terminalia ferdinandiana

25 mg

Equivalent: Terminalia ferdinandiana (Dry)

250 mg


25 mg

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at

Public Summary

Page 2 of

Produced at 29.08.2019 at 04:37:22 AEST

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit for contact information

Similar products

Search alerts related to this product

Share this information